The US Agency for Research and Quality (AHRQ) issued this month a clinical summary guide comparing premixed insulin analogues with other treatments for type 2 diabetes.
The clinical bottom line of the summary:
Premixed insulin analogues and premixed human insulin have similar effects on glycosylated hemoglobin (A1c), and rates of hypoglycemia are similar.
Premixed insulin analogues help achieve lower postprandial glucose levels than premixed human insulin.
Premixed insulin analogues help achieve lower A1c levels than long-acting insulin analogues used alone, but rates of hypoglycemia are higher.
Premixed insulin analogues are linked with more episodes of hypoglycemia than oral diabetes drugs.
Premixed insulin analogues help achieve lower A1c levels than oral diabetes drugs used alone.